Results 111 to 120 of about 1,463,292 (235)

Metamizole induces voriconazole metabolism and results in subtherapeutic voriconazole concentrations

British Journal of Clinical Pharmacology, EarlyView.
Aims Voriconazole is extensively metabolized via cytochrome P450 (CYP) enzymes, predominantly CYP2C19 and CYP3A4. Drugs influencing the activity or expression of CYP enzymes can cause clinically relevant changes in the metabolism and voriconazole exposure. Metamizole is known to induce CYP3A4 and CYP2C19.
Simone D. Baan, Daan J. Touw, Marjolijn N. Lub‐de Hooge, Thijs H. Oude Munnink   +3 more
wiley   +1 more source

Population pharmacokinetic modelling of prednisolone in systemic lupus erythematosus patients: Analysis of exposure and disease activity

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Prednisone is a widely used glucocorticoid in the treatment of lupus, although its dosing is often determined empirically. Prednisolone, the active metabolite of prednisone, is found in its free form in the serum. The goal of this study was to develop a population pharmacokinetic model in patients with systemic lupus erythematosus (SLE ...
Naïm Bouazza, Michaela Semeraro, Gabrielle Lui, Léo Froelicher‐Bournaud, Laure Choupeaux, Jean‐Marc Treluyer, Sihem Benaboud, Joelle Terzic, Eric Hachulla, Philippe Remy, Jérôme Harambat, Alexandre Karras, Caroline Rousset‐Rouviere, Anne Jolivot, Zahir Amoura, Eric Daugas, Aurélie Hummel, Rémi Salomon, Jean‐Christophe Lega, Stéphane Decramer, Alexandre Belot, Delphine Gobert, Nathalie Costedoat‐Chalumeau, Stanislas Faguer, Isabelle Melki, Noémie Jourde‐Chiche, Brigitte Bader‐Meunier   +26 more
wiley   +1 more source

A companion to the preclinical common data elements for rodent models of pediatric acquired epilepsy: A report of the TASK3‐WG1B, Pediatric and Genetic Models Working Group of the ILAE/AES Joint Translational Task Force

Epilepsia Open, EarlyView., 2022
Abstract Epilepsy syndromes during the early years of life may be attributed to an acquired insult, such as hypoxic–ischemic injury, infection, status epilepticus, or brain trauma. These conditions are frequently modeled in experimental rodents to delineate mechanisms of epileptogenesis and investigate novel therapeutic strategies.
Anna‐Maria Katsarou, Hana Kubova, Stéphane Auvin, Massimo Mantegazza, Melissa Barker‐Haliski, Aristea S. Galanopoulou, Christopher A. Reid, Bridgette D. Semple   +7 more
wiley   +1 more source

Relapsing fevers

, 2010
Abstract Louse-borne relapsing fever and tick-borne relapsing fever are characterized by repeated episodes of high fever separated by afebrile periods. They are caused by Borrelia spirochaetes distinct from those responsible for Lyme borrelioses.
openaire   +3 more sources

Medications, epilepsy and climate change: Added layers of complexity

British Journal of Clinical Pharmacology, EarlyView.
Climate change—the global crisis with pervasive health impacts—has adverse consequences for people with epilepsy (PWE) who have low quality of life due to poor seizure control, socioeconomic disadvantages and comorbidities. This review focuses on the potential effects of climate change on the pharmacological characteristics of antiseizure medications ...
Medine I. Gulcebi, Seyhmus Gavas, Sanjay M. Sisodiya   +2 more
wiley   +1 more source

A companion to the preclinical common data elements and case report forms for in vivo rodent neuroimaging: A report of the TASK3‐WG3 Neuroimaging Working Group of the ILAE/AES Joint Translational Task Force

Epilepsia Open, EarlyView., 2022
Abstract The International League Against Epilepsy/American Epilepsy Society (ILAE/AES) Joint Translational Task Force established the TASK3 working groups to create common data elements (CDEs) for various aspects of preclinical epilepsy research studies, which could help improve the standardization of experimental designs.
Erwin A. van Vliet, Riikka Immonen, Ofer Prager, Alon Friedman, Jens P. Bankstahl, David K. Wright, Terence J. O'Brien, Heidrun Potschka, Olli Gröhn, Neil G. Harris   +9 more
wiley   +1 more source

From silence to academic engagement: How refugee children with disabilities access learning through inclusive ‘artful’ schools in Canada

British Educational Research Journal, EarlyView.
Abstract Many newcomer children spend a ‘silent year’ in elementary school classrooms while they adjust to a new culture and language. This often delays inclusion in learning and forming friendships with peers. For refugee children with disabilities (RCDs) this phase may last for 3 years or more, impacting their mental health and sense of belonging ...
Susan Barber
wiley   +1 more source

Altering 15‐Lipoxygenases to 18‐Lipoxygenases and Their Application to the Production of 5,18‐Dihydroxyeicosapentaenoic Acids

Biotechnology and Bioengineering, EarlyView.
15R‐ and 15S‐lipoxygenases (15R‐ and 15S‐LOXs) were engineered into 18R‐ and 18S‐LOXs, respectively. Escherichia coli expressing these enzymes converted eicosapentaenoic acid into 18R‐ and 18S‐hydroxyeicosapentaenoic acids (18R‐ and 18S‐HEPEs), respectively.
Jin Lee, Su‐Hwan Kang, Tae‐Eui Lee, Deok‐Kun Oh   +3 more
wiley   +1 more source

An open‐label, single‐arm, multicenter, phase II trial of bireociclib as monotherapy for heavily pretreated HR‐positive, HER2‐negative advanced breast cancer patients: BRIGHT‐1 trial

Cancer Communications, EarlyView.
Abstract Background Bireociclib (XZP‐3287) is a novel selective cyclin‐dependent kinase 4 and 6 (CDK4/6) inhibitor, with a favorable safety profile demonstrated in preclinical and phase I studies. BRIGHT‐1 aimed to further explore the efficacy and safety of bireociclib monotherapy in patients with locally advanced, recurrent or metastatic, hormone ...
Jiayu Wang, Qingyuan Zhang, Tao Sun, Huiping Li, Ying Cheng, Zhongsheng Tong, Huihui Li, Wei Li, Jingfen Wang, Yuee Teng, Xinhong Wu, Jing Cheng, Zhendong Chen, Zhengqiu Zhu, Li Wang, Mingming Liu, Xianghui Duan, Lingmei Xu, Binghe Xu   +18 more
wiley   +1 more source

A phase II basket trial of dual anti‐CTLA‐4 and anti‐PD‐1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort

Cancer Communications, EarlyView.
Abstract Background The combined use of anti‐programmed cell death protein 1 (PD‐1)/anti‐cytotoxic T‐lymphocyte associated protein 4 (CTLA‐4) checkpoint inhibitors has been effective in various cancer types. The Southwest Oncology Group (SWOG) Dual Anti‐CTLA‐4 and Anti‐PD‐1 Blockade in Rare Tumors (DART) S1609 study investigated ipilimumab and ...
Young Kwang Chae, Megan Othus, Sandip Pravin Patel, Raid Aljumaily, Khine Z. Win, Tanya Pejovic, Sajeve S. Thomas, William R. Robinson III, Hye Sung Kim, Liam Il‐Young Chung, Christine M. McLeod, Helen X. Chen, Elad Sharon, Howard Streicher, Christopher W. Ryan, Charles D. Blanke, Razelle Kurzrock   +16 more
wiley   +1 more source